• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.T细胞/组织细胞丰富的大B细胞淋巴瘤对CD19导向的嵌合抗原受体T细胞疗法的原发性耐药
Blood. 2021 Jun 17;137(24):3454-3459. doi: 10.1182/blood.2020009148.
2
Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma.嵌合抗原受体T细胞疗法对复发/难治性大B细胞淋巴瘤老年脆弱患者的疗效与安全性
Haematologica. 2021 Jan 1;106(1):255-258. doi: 10.3324/haematol.2019.243246.
3
CD19-directed CART therapy for T-cell/histiocyte-rich large B-cell lymphoma.CD19 靶向嵌合抗原受体 T 细胞治疗 T 细胞/组织细胞丰富型大 B 细胞淋巴瘤。
Blood Adv. 2024 Oct 22;8(20):5290-5296. doi: 10.1182/bloodadvances.2024013863.
4
Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma.在难治性弥漫性大B细胞淋巴瘤中，抗CD19嵌合抗原受体T细胞疗法后，PD-1抑制导致肿瘤快速消退。
Bone Marrow Transplant. 2020 Jun;55(6):1184-1187. doi: 10.1038/s41409-019-0657-3. Epub 2019 Aug 30.
5
[Relapse mechanism and coping strategies of CD19 chimeric antigen receptor T cells in the treatment of diffuse large B-cell lymphoma].[CD19嵌合抗原受体T细胞治疗弥漫性大B细胞淋巴瘤的复发机制及应对策略]
Zhonghua Xue Ye Xue Za Zhi. 2022 Sep 14;43(9):788-792. doi: 10.3760/cma.j.issn.0253-2727.2022.09.014.
6
Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clinic experience.接受抗CD-19嵌合抗原受体T细胞疗法治疗大B细胞淋巴瘤患者中细胞因子释放综合征和神经毒性与疗效的真实世界关联：梅奥诊所的经验
Leuk Lymphoma. 2024 Mar;65(3):389-393. doi: 10.1080/10428194.2023.2285236. Epub 2023 Nov 30.
7
Acute myeloid leukemia development soon after anti-CD19 chimeric antigen receptor T-cell infusion in a patient with refractory diffuse large B-cell lymphoma and pre-existing clonal hematopoiesis.一名患有难治性弥漫性大B细胞淋巴瘤且存在克隆性造血的患者在接受抗CD19嵌合抗原受体T细胞输注后不久发生急性髓系白血病。
Haematologica. 2023 Jan 1;108(1):290-294. doi: 10.3324/haematol.2022.281351.
8
Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations.嵌合抗原受体T细胞疗法治疗HIV相关弥漫性大B细胞淋巴瘤：病例报告及管理建议
Bone Marrow Transplant. 2021 Mar;56(3):679-682. doi: 10.1038/s41409-020-01018-7. Epub 2020 Aug 6.
9
Unresolved questions in the second-line use of CAR-T cells for diffuse large B cell lymphoma.嵌合抗原受体T细胞（CAR-T）用于弥漫性大B细胞淋巴瘤二线治疗中的未解决问题。
Nat Med. 2022 Dec;28(12):2458-2459. doi: 10.1038/s41591-022-02067-9.
10
Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy.早期正电子发射断层扫描在接受抗CD19嵌合抗原受体T细胞疗法治疗的大B细胞淋巴瘤患者中的预后价值
Haematologica. 2023 Dec 1;108(12):3433-3437. doi: 10.3324/haematol.2022.282345.

引用本文的文献

1
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry.接受抗CD19嵌合抗原受体T细胞（CAR-T）治疗的复发或难治性原发性纵隔B细胞淋巴瘤患者的结局：CARTHYM研究，一项来自法国国家DESCAR-T注册机构的研究
Hemasphere. 2025 Feb 18;9(2):e70091. doi: 10.1002/hem3.70091. eCollection 2025 Feb.
2
Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study.富含T细胞/组织细胞的大B细胞淋巴瘤的嵌合抗原受体T细胞治疗结果及疾病进展后的后续治疗策略：一项GELTAMO/GETH研究
Hemasphere. 2025 Feb 4;9(2):e70077. doi: 10.1002/hem3.70077. eCollection 2025 Feb.
3
High-Dose Chemotherapy and Autologous or Allogeneic Transplantation in Aggressive B-Cell Lymphoma-Is There Still a Role?大剂量化疗联合自体或异基因移植治疗侵袭性 B 细胞淋巴瘤：是否仍有一席之地？
Cells. 2024 Oct 27;13(21):1780. doi: 10.3390/cells13211780.
4
Hemophagocytic lymphohistiocytosis in a patient with Epstein-Barr virus-positive diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.一名接受嵌合抗原受体T细胞疗法治疗的爱泼斯坦-巴尔病毒阳性弥漫性大B细胞淋巴瘤患者发生噬血细胞性淋巴组织细胞增生症。
Immunotherapy. 2024;16(18-19):1105-1111. doi: 10.1080/1750743X.2024.2409622. Epub 2024 Oct 17.
5
CARs to the rescue: rare aggressive lymphoma gets a power up.嵌合抗原受体来救援：罕见侵袭性淋巴瘤获得助力。
Blood Adv. 2024 Oct 22;8(20):5342-5343. doi: 10.1182/bloodadvances.2024014118.
6
Immune checkpoint blockade and CAR T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma: Challenges and opportunities.T细胞/组织细胞丰富的大B细胞淋巴瘤中的免疫检查点阻断和嵌合抗原受体T细胞疗法：挑战与机遇
Heliyon. 2024 Sep 18;10(18):e38023. doi: 10.1016/j.heliyon.2024.e38023. eCollection 2024 Sep 30.
7
Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study.自体干细胞移植治疗 T 细胞/组织细胞丰富型大 B 细胞淋巴瘤：EBMT 淋巴瘤工作组研究。
Blood Adv. 2024 Nov 12;8(21):5571-5578. doi: 10.1182/bloodadvances.2024013152.
8
CD19-directed CART therapy for T-cell/histiocyte-rich large B-cell lymphoma.CD19 靶向嵌合抗原受体 T 细胞治疗 T 细胞/组织细胞丰富型大 B 细胞淋巴瘤。
Blood Adv. 2024 Oct 22;8(20):5290-5296. doi: 10.1182/bloodadvances.2024013863.
9
CAR T-cell therapy in aggressive lymphomas-identifying prognostic and predictive markers.嵌合抗原受体 T 细胞疗法治疗侵袭性淋巴瘤——寻找预后和预测标志物。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):357-363. doi: 10.1182/hematology.2023000436.
10
[Efficacy and safety of fourth-generation CD19 CAR-T expressing IL7 and CCL19 along with PD-1 monoclonal antibody for relapsed or refractory large B-cell lymphoma].表达IL7和CCL19的第四代CD19嵌合抗原受体T细胞联合程序性死亡蛋白1单克隆抗体治疗复发或难治性大B细胞淋巴瘤的疗效和安全性
Zhonghua Xue Ye Xue Za Zhi. 2023 Oct 14;44(10):820-824. doi: 10.3760/cma.j.issn.0253-2727.2023.10.005.

本文引用的文献

1
Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma.空间特征将 PD-1 免疫逃逸鉴定为 T 细胞/组织细胞丰富型大 B 细胞淋巴瘤的一个决定性特征。
Blood. 2021 Mar 11;137(10):1353-1364. doi: 10.1182/blood.2020006464.
2
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma.高代谢肿瘤体积与 axicabtagene ciloleucel 在大 B 细胞淋巴瘤中的疗效降低有关。
Blood Adv. 2020 Jul 28;4(14):3268-3276. doi: 10.1182/bloodadvances.2020001900.
3
The immune landscape and response to immune checkpoint blockade therapy in lymphoma.淋巴瘤的免疫景观与免疫检查点阻断治疗反应。
Blood. 2020 Feb 20;135(8):523-533. doi: 10.1182/blood.2019000847.
4
Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base.T 细胞/组织细胞丰富型大 B 细胞淋巴瘤患者的临床特征和生存分析：国家癌症数据库分析。
Leuk Lymphoma. 2019 Dec;60(14):3426-3433. doi: 10.1080/10428194.2019.1639166. Epub 2019 Jul 9.
5
gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype.基因改变鉴定出具有 T 细胞炎症表型的弥漫性大 B 细胞淋巴瘤亚群。
Blood. 2019 May 23;133(21):2279-2290. doi: 10.1182/blood-2018-10-879015. Epub 2019 Mar 25.
6
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.ASTCT 细胞因子释放综合征和免疫效应细胞相关神经系统毒性的共识分级标准。
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.
7
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.阿基仑赛注射液治疗难治性大 B 细胞淋巴瘤的长期安全性和疗效（ZUMA-1）：一项单臂、多中心、1-2 期临床试验。
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
8
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
9
, , , and are frequently mutated in T-cell/histiocyte-rich large B-cell lymphoma.在 T 细胞/组织细胞丰富性大 B 细胞淋巴瘤中，经常发生 、 、 和 的突变。
Haematologica. 2019 Feb;104(2):330-337. doi: 10.3324/haematol.2018.203224. Epub 2018 Sep 13.
10
T-cell/histiocyte-rich large B-cell lymphoma.富于T细胞/组织细胞的大B细胞淋巴瘤
Haematologica. 2010 Mar;95(3):352-6. doi: 10.3324/haematol.2009.016931.

Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.

作者信息

Trujillo Jonathan A, Godfrey James, Hu Yifei, Huang Jun, Smith Sonali M, Frigault Matthew J, DeFilipp Zachariah, Appelbaum Daniel, Pu Yonglin, Feinberg Nicholas, Althaus Thomas, Bishop Michael R, Riedell Peter A, Kline Justin

机构信息

Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL.

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.

出版信息

Blood. 2021 Jun 17;137(24):3454-3459. doi: 10.1182/blood.2020009148.

DOI:10.1182/blood.2020009148
PMID:33881502
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8212512/
Abstract
摘要